Neurocrine Biosciences Inc (NBIX)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Neurocrine Biosciences Inc is a Healthcare company with a market capitalization of $15.19B and a trailing P/E ratio of 21.8.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $1.94 | $1.70 | +14.1% |
| Q4 2025 | February 11, 2026 | $1.88 | $2.30 | -18.3% |
| Q3 2025 | October 28, 2025 | $2.17 | $2.07 | +4.8% |
| Q2 2025 | July 30, 2025 | $1.65 | $1.50 | +10.0% |
| Q1 2025 | May 5, 2025 | $0.70 | $1.09 | -35.8% |
| Q4 2024 | February 6, 2025 | $1.69 | $1.93 | -12.4% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 5,334,688 | 5.16% | 4.9 | -3.5% |
| June 30, 2026 | 5,530,854 | 5.35% | 4.2 | -2.8% |
| June 15, 2026 | 5,690,488 | 5.50% | 5.0 | +2.9% |
| May 29, 2026 | 5,529,509 | 5.35% | 5.0 | +7.2% |
| May 15, 2026 | 5,160,707 | 4.99% | 3.7 | -13.9% |
| April 30, 2026 | 5,992,527 | 5.85% | 5.2 | +6.2% |
| April 15, 2026 | 5,644,452 | 5.51% | 4.9 | +23.9% |
| March 31, 2026 | 4,557,132 | 4.45% | 4.6 | +18.1% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is Neurocrine Biosciences Inc's market cap?
As of August 13, 2026, Neurocrine Biosciences Inc (NBIX) has a market capitalization of $15.19B.
What is Neurocrine Biosciences Inc's P/E ratio?
Neurocrine Biosciences Inc trades at a trailing price-to-earnings (P/E) ratio of 21.8. Its forward P/E is 22.1.
Does Neurocrine Biosciences Inc pay a dividend?
Neurocrine Biosciences Inc does not currently pay a dividend.
What sector is NBIX in?
Neurocrine Biosciences Inc is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What is Neurocrine Biosciences Inc's short interest?
As of the July 15, 2026 FINRA settlement, 5,334,688 NBIX shares were sold short, or 5.16% of shares outstanding. Days to cover: 4.9. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Neurocrine Biosciences Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Neurocrine Biosciences Inc reported revenue of $2.86B and net income of $478.60M.
Ask your own questions about NBIX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.